{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"title":"Total Deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Deaths on-treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 12.5 months (treatment duration ranged from 0.2 to 11.5 months). Deaths post treatment survival follow up were collected after the on treatment period, up to approximately 51 months.","groups":[{"description":"Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).","id":"OG000","title":"Standard of Care With Midostaurin"},{"description":"Patients received standard of care alone in the post SCT setting","id":"OG001","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"Clinical Database Population: all treated patients","reportingStatus":"POSTED","timeFrame":"approx. 12.5 months, approx. 51 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}